Metabolic medicines

Ecnoglutide

A GLP-1 receptor agonist with a phase 3 obesity trial and sponsor-reported approval in China.

Randomized phase 3 human evidence; China-specific status

Ecnoglutide molecular structure — Structure reference · C194H304N48O61

Practical use

Reviewed practical notes

Check the country: Verify the relevant regulator and indication for the place where care occurs.
Match the analysis: Do not compare one drug’s treatment-policy estimate with another’s selected completer result.
Keep outcome claims bounded: Weight change alone does not establish fewer cardiovascular events.

Published SLIMMER trial

Sciwind China approval announcement

Overview

Ecnoglutide is a GLP-1 receptor agonist described as favoring cAMP signaling. That signaling profile is a mechanistic distinction, not proof that it is safer or more effective than another GLP-1 medicine. Its trial results and approval jurisdiction need to be considered separately.

Risks and limitations

Gastrointestinal effects were the most common adverse events in the cited trial and were usually mild or moderate. Some active-treatment participants discontinued because of adverse effects. A 40-week trial does not characterize every uncommon harm or long-term outcome.

How to read this

Sciwind announced Chinese NMPA approval for chronic weight management in March 2026. This guide attributes that status to the sponsor announcement; it does not imply approval in the United States or any other jurisdiction.

Research explained

SLIMMER phase 3 trial

Who was studied

664 adults in China with overweight or obesity, without diabetes, randomized to three active groups or placebo for 40 weeks.

What was found

Under the treatment-policy analysis, mean weight change ranged from −9.1% to −13.2% with ecnoglutide versus +0.1% with placebo. Gastrointestinal effects were common.

What it cannot establish

Population, follow-up and analysis method matter. The result is not a head-to-head comparison with another obesity medicine and does not establish cardiovascular outcome benefit.

Read the original study

Different time points produce different headline numbers

The published trial abstract reports the primary 40-week results, while the sponsor’s approval announcement highlights 48-week results. Those percentages describe different time points. Retain both the follow-up duration and analysis method before comparing outcomes.

Supporting source

Keep the country attached to approval

The March 2026 announcement concerns China’s regulator and a defined indication. A positive trial, a local authorization and worldwide availability are three different claims.